Therapeutic delivery of microRNA-143 by cationic lipoplexes for non-small cell lung cancer treatment in vivo

ConclusionsOur results suggested that CL-pVAX-miR-143 might be a promising strategy for clinical treatment of non-small cell lung cancer, especially for advanced NSCLC with metastasis.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Conclusion: The TIMP3 silencing observed in the NLNT and its negative correlation with presurgical expression of miR-20a (from serum exosomes), suggest that miRs can influence ECM remodeling at a distance from the center of the lesion. The miRs expression pattern in serum obtained before surgery significantly differs between AC and SCC subtypes. Moreover, decreased TIMP3 expression in NLNT (in SCC group) negatively correlates with the amount of tobacco smoked in a lifetime in PY.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Non Small Cell Lung Cancer Interventions:   Drug: anti-PD-1 or anti-PD-L1;   Drug: EGFR-TKI, ALK inhibitor, ROS1 inhibitor;   Drug: investigator decided Sponsor:   Shanghai Chest Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We examined LATS2 protein expression by immunohistochemistry in 184 resected NSCLC specimens using tissue microarrays. Low LATS2 expression was significantly related to disease recurrence (p = 0.047). In survival analysis, the low LATS2 expression group showed a statistically poorer overall survival (OS) (p = 0.004) and disease-free survival (DFS) (p = 0.014) than the high expression group. In multivariate analysis, downregulated LATS2 expression in NSCLC could be an independent prognostic factor of poor OS and DFS. Furthermore, we evaluated the prognostic signifi...
Source: Polish Journal of Pathology - Category: Pathology Tags: Pol J Pathol Source Type: research
In this study, we aimed to investigate the prognostic significance of CD63 expression in non-small cell lung cancer (NSCLC). CD63 expression was evaluated in 133 cases of NSCLC via immunohistochemical staining using tissue microarray blocks. We assessed the relationship between CD63 expression and clinicopathological characteristics, as well as the prognostic significance of CD63 expression in NSCLC. CD63 expression was significantly correlated with patient gender (p 
Source: Polish Journal of Pathology - Category: Pathology Tags: Pol J Pathol Source Type: research
In conclusion, the present study demonstrated that PCAT19 negatively regulates the p53 tumor-suppression pathway, promoting cancer cell proliferation in patients with NSCLC. PMID: 31819778 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Liu W, Zhang C, Cao H, Shi D, Zhao S, Liang T, Hou G Abstract Lung cancer, especially non-small cell lung cancer (NSCLC), is the most common malignant tumor associated with poor prognosis. Angiogenesis plays a vital role in NSCLC, and could be used in tumor staging and therapy evaluation. CD93 (C1q receptor) is reportedly a key regulator of tumor angiogenesis. In the present study, the efficacy and specificity of a 125I-labeled CD93-specific monoclonal antibody (125I-anti-CD93 mAb) in detecting NSCLC xenografts were analyzed, and the association between CD93 expression and 125I-anti-CD93 mAb uptake by tumo...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
ConclusionsSBRT for clinically diagnosed lung cancers is efficacious in appropriately selected patients, with similar outcomes as those with pathologic diagnosis. Thorough clinical and radiographic evaluation in a multidisciplinary setting is critical to the management of these patients.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Oncogene, Published online: 12 December 2019; doi:10.1038/s41388-019-1143-5Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation
Source: Oncogene - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Toxicology